natgillin/translations-raw huggingface dataset:
At han ikke bør donere sæd under behandlingen og i en uge efter, thalidomidbehandlingen afsluttes
That he should not donate semen during therapy and for one week following discontinuation of thalidomide
At han ikke må dele behandlingen med nogen anden person
That he should not share the treatment with any other person
At han ikke må donere sæd eller sperm under behandlingen (herunder under dosisafbrydelser) og i 7 dage efter ophør med pomalidomid
That he should not donate semen or sperm during therapy (including during dose interruptions) and for 7 days after discontinuation of pomalidomide treatment
At han ikke må donere sæd eller sperm under behandlingen (herunder under dosisafbrydelser) og i 7 dage efter seponering af pomalidomid
That he should not donate semen or sperm during therapy (including during dose interruptions) and for 7 days after discontinuation of pomalidomide treatment
At han ikke må donere sæd under behandlingen og i en uge efter thalidomidbehandlingen afsluttes
That he should not donate semen during therapy and for one week after discontinuation of thalidomide
At han skal informere den behandlende læge omgående, hvis hans partner bliver gravid
That if his partner becomes pregnant he should inform his treating doctor immediately
At han skal informere den behandlende læge omgående, hvis hans partner bliver gravid, imens han tager eller kort tid efter, at han er ophørt med pomalidomid.
That if his partner becomes pregnant whilst he is taking pomalidomide or shortly after he has stopped taking pomalidomide he should inform his treating doctor immediately
At han skal informere den behandlende læge omgående, hvis hans partner bliver gravid, imens han tager, eller kort tid efter, at han er ophørt med Revlimid
That if his partner becomes pregnant whilst he is taking Revlimid or shortly after he has stopped taking Revlimid he should inform his treating doctor immediately
At han skal informere den behandlende læge omgående, hvis hans partner bliver gravid.
That if his partner becomes pregnant he should inform his treating doctor immediately
At han skal levere kapslerne tilbage til apoteket ved behandlingens seponering
That he should return the capsules to the pharmacist at the end of treatment
At han, hvis hans partner bliver gravid, skal underrette den behandlende læge med det samme, og altid anvende kondom
That if his partner becomes pregnant he should inform his treating doctor immediately and always use a condom
At han, hvis hans partner bliver gravid, skal underrette sin behandlende læge med det samme og altid bruge kondom under samleje
That if his partner becomes pregnant he should inform his treating doctor immediately and always use a condom during intercourse
At have en skinne på ved sengetid i op til 4 måneder.
Wear the splint at bedtime for up to 4 months.
At holde den injicerede hånd eleveret så meget som muligt, indtil dagen efter manipulation af fingeren.
To elevate the injected hand as much as possible until the day after the finger extension procedure.
at holde den injicerede hånd løftet op så meget som muligt indtil dagen efter fingermanipulationen.
To elevate the injected hand as much as possible until the day after the finger extension procedure.
at holde øje med bestemte tegn og symptomer, som kan indikere leversygdom eller infektion, og hvis nogen af disse opstår, om at kontakte lægen med det samme.
To pay attention to certain signs and symptoms which might indicate liver disease or infection, and if any of these occur, to contact their doctor/HCP promptly
At hormonale præventionsmidler alene ikke er effektive
That hormonal contraceptives on their own are not effective
At hormonelle præventionsmidler alene ikke er effektive
That hormonal contraceptives on their own are not effective
At hun ikke må dele behandlingen med andre
That she should not share the treatment with any other person
At hun ikke må dele behandlingen med nogen anden person
That she should not share the treatment with any other person
At hun ikke må donere blod under behandlingen og i en uge efter thalidomidbehandlingen afsluttes
That she should not donate blood during therapy and for one week following discontinuation of thalidomide
At hun skal levere kapslerne tilbage til apoteket ved behandlingens afslutning
That she should return the capsules to the pharmacist at the end of treatment
At hun, hvis hun er gravid eller planlægger at blive gravid, ikke må tage Thalidomide Celgene
That if she is pregnant or plans to be, she must not take Thalidomide Celgene
At hun, hvis hun har brug for at ændre eller stoppe sin præventionsmetode, skal informere
That if she needs to change or stop using her method of contraception she should inform:
At hun, hvis hun har brug for at ændre eller stoppe sin svangerskabsforebyggende metode, skal informere
That if she needs to change or stop using her method of contraception she should inform:
At hvis knogleabnormiteter påvises eller mistænkes, skal konsultation med en endokrinolog og/eller en nefrolog foretages.
That if bone abnormalities are detected or suspected then consultation with an endocrinologist and/or nephrologist should be obtained
At hvis kreatininclearance bekræftes som < 50 ml/min, eller serumphosphat falder til
That if creatinine clearance is confirmed as < 50 mL/min or serum phosphate decreases to
At hvis serumphosphat bekræftes til at være < 3,0 mg/dl (0,96 mmol/l) hos pædiatriske patienter, der får tenofovirdisoproxilfumarat, skal vurderingen af nyrefunktionen gentages inden for en uge.
That if serum phosphate is confirmed to be < 3.0 mg/dl (0.96 mmol/l) in any paediatric patient receiving tenofovir disoproxil fumarate, renal function should be re-evaluated within one week.
at hæmme immunforsvaret og forebygge svigt af
to lower immune response or prevent organ transplant failures
At hæmmere kan øge risikoen for bivirkninger, specielt forlængelse af QT-intervallet
That inhibitors may increase the potential for adverse drug reactions in particular QT interval prolongation.
at hætteglasset ikke er beskadiget, og at forseglingen ikke er brudt
the vial is not damaged and the seal is not broken
at høre eller se billeder, der ikke er til stede,
hearing or seeing images that are not present,
At ikke anvendte kapsler skal leveres tilbage til apoteket ved behandlingens seponering
That any unused capsules should be returned to the pharmacist at the end of the treatment
At indrapportere alle graviditeter, der opstår under behandling.
To report all cases of pregnancy occurring during therapy.
At indsende en opdateret analyse af samlet overlevelse for studiet CNTO328MCD2001
To submit an updated analysis of overall survival for study CNTO328MCD2001
At indsende en opdateret analyse af samlet overlevelse for studiet CNTO328MCD2001
To submit an updated analysis of overall survival for study CNTO328MCD2002
At indsende en opdatret status og tilgængelige resultater inkl. alle præliminære analyser i den simplificerede PSUR.
Updated status and available results, including all preliminary analysis, have to be provided in the (simplified) PSUR
at infektion skal være udelukket, før immunosuppressiv behandling påbegyndes at alle patienter skal indgå i et langsigtet overvågningsprogram
the need to exclude infection before starting immunosuppressant treatment the need for all patients to be entered into a long term surveillance programme
At informere patienter og læger om risikoen for alvorlig leverskade samt procedurer i forhold til korrekt håndtering af denne risiko med det formål at minimere forekomsten og sværhedsgraden.
To educate patients and physicians about the risk of severe hepatic injury and the procedures related to the appropriate management of this risk to minimise its occurrence and its severity.
At insulin glargin 100 enheder/ml og insulin glargin 300 enheder/ml (Toujeo 300 enheder/ml) ikke er bioækvivalente og derfor ikke kan erstatte hinanden uden dosisjustering.
That insulin glargine 100 units/ml and insulin glargine 300 units/ml (Toujeo 300 units/ml) are not bioequivalent and are therefore not interchangeable without dose adjustment.
at kravene til rekonstitution er forskellige ved intravenøs (i.v.) og subkutan (s.c.) anvendelse vejledning i dosering med eksempler: Sådan beregnes patientens legemsoverflade og det nødvendige volumen rekonstitueret Bortezomib SUN (både til i.v. og s.c. anvendelse) til forskellige arealer af legemsoverfladen.
Bortezomib SUN dose. different reconstitution requirements for intravenous (IV) or subcutaneous (SC) use dosing instructions and examples: how to calculate the body surface area of a patient and the volume of reconstituted Bortezomib SUN (both IV and SC use) required for different body surface areas.
At kronisk administration af Volibris til dyr er blevet forbundet med udvikling af testikulær tubulusatrofi og nedsat fertilitet.
That chronic administration of Volibris in animals has been linked to testicular tubular atrophy and impaired fertility.
At kvinder i den fertile alder skal have foretaget en graviditetstest umiddelbart før første ordination og efterfølgende hver måned, så længe de er i behandling med Volibris.
Women with child-bearing potential must have a pregnancy test immediately prior to the first prescription and at monthly intervals whilst taking Volibris.
At kvinder i den fødedygtige alder skal anvende effektiv prævention
That women of child bearing potential must use effective contraception
At kvinder i den fødedygtige alder skal bruge sikker prævention, og at de skal informere deres læge om mulig graviditet, før udskrivning af en ny recept.
The need to ensure that women of child bearing age are using effective contraception and that patients should inform their doctors of any possibility of pregnancy before a new prescription is issued
At lenalidomid er teratogent hos dyr og forventes at have teratogen virkning hos mennesker
That lenalidomide is teratogenic in animals and is expected to be teratogenic in humans
at lægemidlet skal håndteres under sterile betingelser
need to handling the medicinal product in sterile setting
At læger opfordres til at inkludere patienter i opfølgningsprogrammet, Transthyretin Amyloidosis Outcome Survey (THAOS) og at de får oplysninger om, hvordan patienter inkluderes i dette internationale sygdomsregister.
That physicians are encouraged to enter patients in the Transthyretin Amyloidosis Outcome Survey (THAOS) and provided with details how to enroll patients into this international disease registry
At MACI er et autologt præparat og kun må administreres til den patient, som biopsien er taget fra.
That MACI is an autologous product and should only be administered to the patient that the biopsy was taken from.
at mindske risikoen for nye infektioner af yveret i goldperioden
reduce the risk of new infections of the udder during the dry period,
at mindske ubehag
reduce discomfort.
at mindske udsivning af mælk ved goldning (det tidspunkt, hvor man holder op med at malke)
reduce milk leakage at drying off (the point at which the cow is no longer milked),
At minimumskriterier for data overført til ”individual case safety reports” giver mulighed for at evaluere og identificere den administrerede vaccine inklusive produktnavn, fremstiller og batchnummer.
The minimal data elements to be transmitted in individual case safety reports in order to facilitate the evaluation and the identification of the vaccine administered to each subject, including the invented name, the vaccine manufacturer and the batch number.
at monitorere
considered necessary, a monitoring
at monitorere blodtrykket under behandlingsproceduren at give støttebehandling, hvis patienterne oplever en smerteforøgelse under administrationen af Qutenza hos patienter med ustabil eller dårligt kontrolleret hypertension eller kardiovaskulær sygdom: forud for behandlingen med Qutenza at vurdere risikoen for uønskede kardiovaskulære hændelser som følge af den potentielle belastning, som proceduren medfører.
to monitor blood pressure during the treatment procedure to provide supportive treatment if patients experience increased pain during Qutenza administration in patients with unstable or poorly controlled hypertension or cardiovascular disease: to evaluate, prior to initiating Qutenza treatment, the risk of adverse cardiovascular eventsdue to the potential stress of the procedure.
at nedsætte cobicistat
decrease cobicistat plasma
at nedsætte mængden af calcium i blodet hos voksne patienter, hvor det er for højt som følge af tilstedeværelsen af en tumor.
to reduce the amount of calcium in the blood in adult patients where it is too high due to the presence of a tumour.
At nedsætte mængden af calcium i blodet hos voksne, hvor det er for højt som følge af tilstedeværelsen af en tumor.
To reduce the amount of calcium in the blood in adult patients where it is too high due to the presence of a tumour.
at opløsningen er klar og farveløs eller svag gul, samt ikke indeholder partikler. at injektionssprøjten ikke tidligere har været åbnet, og ikke er beskadiget.
the solution is clear and colourless to slightly yellow and doesn’t contain particles the syringe has not been opened or damaged
at opløsningen er klar og farveløs, samt ikke indeholder partikler at injektionssprøjten ikke tidligere har været åbnet, og ikke er beskadiget
the solution is clear and colourless and doesn’t contain particles the syringe has not been opened or damaged
at opløsningen er klar, farveløs og ikke indeholder partikler at injektionssprøjten ikke tidligere har været åbnet, og at denne ikke er beskadiget.
the solution is clear and colourless and doesn’t contain particles the syringe has not been opened or damaged
at opløsningen er klar, farveløs til svag gul og ikke indeholder partikler at injektionssprøjten ikke tidligere har været åbnet, og at denne ikke er beskadiget.
the solution is clear and colourless to slightly yellow and doesn’t contain particles the syringe has not been opened or damaged
at opløsningen i den fyldte injektionssprøjte er klar til svagt opaliserende (har et perlemorsagtigt skær), og at den er farveløs til svagt gul
the solution in the pre-filled syringe is clear to slightly opalescent (having a pearl-like shine) and colourless to light yellow
at opløsningen i den fyldte injektionssprøjte er klar til svagt opaliserende (har et perlemorsagtigt skær), og at den er farveløs til svagt gul.
the solution in the pre-filled syringe is clear to slightly opalescent (having a pearl-like shine) and colourless to light yellow
at opløsningen i den fyldte injektionssprøjte ikke er misfarvet eller uklar, og at den ikke indeholder fremmede partikler at opløsningen i den fyldte injektionssprøjte ikke er frosset.
the solution in the pre-filled syringe is not discoloured or cloudy and does not contain any foreign particles the solution in the pre-filled syringe is not frozen.
at opløsningen i den fyldte injektionssprøjte ikke er misfarvet eller uklar, og at den ikke indeholder fremmede partikler. at opløsningen i den fyldte injektionssprøjte ikke er frosset.
the solution in the pre-filled syringe is not discoloured or cloudy and does not contain any foreign particles the solution in the pre-filled syringe is not frozen.
at opløsningen i hætteglasset er klar til svagt opaliserende (har et perlemorsagtigt skær) og at den er farveløs til svagt gul
the solution in the vial is clear to slightly opalescent (having a pearl-like shine) and colourless to light yellow
at opløsningen i hætteglasset er klar til svagt opaliserende (har et perlemorsagtigt skær), og at den er farveløs til svagt gul
the solution in the vial is clear to slightly opalescent (having a pearl-like shine) and colourless to light yellow
at opløsningen ikke er misfarvet eller uklar og at den ikke indeholder fremmede partikler at opløsningen ikke er frossen.
the solution is not discoloured or cloudy and does not contain any foreign particles the solution is not frozen.
at opløsningen ikke er misfarvet eller uklar, og at den ikke indeholder fremmede partikler at opløsningen ikke er frossen
the solution is not discoloured or cloudy and does not contain any foreign particles the solution is not frozen.
At patienten får Ruconest til behandling af akutte anfald af hereditært angioødem
That they are receiving Ruconest for treatment of acute attack of hereditary angioedema
At patienten ikke bør donere blod
That the patient should not donate blood
At patienten ikke må amme under behandlingen og i 20 måneder efter deres sidste dosis
That the patient should not breastfeed during treatment and for 20 months after their final dose
At patienten ikke må amme under behandlingen og i 24 måneder efter den sidste dosis
That the patient should not breastfeed during treatment and for 24 months after their final dose
At patienten ikke må donere blod
That the patient should not donate blood
At patienten ikke må give pomalidomid til andre personer
That the patient should not give pomalidomide to any other person
At patienten ikke må give Revlimid til andre personer
That the patient should not give Revlimid to any other person
At patienten ikke må give Volibris til andre.
That the patient should not give Volibris to any other person.
At patienten ikke må være bloddonor under behandlingen (herunder under dosisafbrydelser) og i 7 dage efter ophør med pomalidomid
That the patient should not donate blood during therapy (including during dose interruptions) and for 7 days after discontinuation of pomalidomide treatment
At patienten ikke må være bloddonor under behandlingen og i 24 måneder efter den sidste dosis
That the patient should not donate blood during treatment and for 24 months after their final dose
At patienten skal informere en sundhedsperson om alle bivirkninger
That the patient should tell the healthcare professional about any adverse event
At patienten skal informere lægen om en hvilken som helst bivirkning
That the patient should tell the healthcare professional about any adverse event
At patienten skal informere lægen om enhver bivirkning.
That the patient should tell their doctor about any adverse event.
at patienten skal kontakte lægen:
The need to contact the treating physician if they experience the following events:
At patienten skal oplyse lægen om enhver bivirkning
That the patient should tell their doctor about any adverse events
At patienten skal underrette lægen om alle utilsigtede hændelser
That the patient should tell their doctor about any adverse events
At patienten straks skal kontakte lægen, hvis hun tror, hun er gravid, og at anden behandling igangsættes, hvis kvinden er gravid.
That the patient should contact her doctor immediately if pregnancy is suspected and that alternative therapy should be initiated if pregnancy confirmed.
At patientens nyrefunktion skal vurderes, før Emtricitabine/Tenofovir disoproxil Zentiva- behandlingen påbegyndes (baseline-nyrefunktion)
That patients should have their baseline renal function assessed prior to initiating Emtricitabine/Tenofovir disoproxil Zentiva therapy
At patientens nyrefunktion skal vurderes, før Truvada-behandlingen påbegyndes (baseline- nyrefunktion)
That patients should have their baseline renal function assessed prior to initiating Truvada therapy
At patienter ikke må donere blod under behandling og i mindst 20 måneder efter deres sidste dosis
That the patient should not donate blood during treatment and for at least 20 months after their final dose
At patienter skal informeres om, at:
That patients should be counselled that:
At patienter, der tidligere har seponeret behandlingen med tenofovirdisoproxilfumarat på grund af nyretoksicitet, ikke bør behandles med Stribild.
That patients who have previously discontinued treatment with tenofovir disoproxil fumarate due to renal toxicity should not be treated with Stribild.
At patienter, som behandles med Ruconest, skal overvåges for kliniske tegn og symptomer på overfølsomhed under administrationen.
That patients treated with Ruconest should be monitored for clinical signs and symptoms of hypersensitivity during administration.
At patienterne bør have deres nyrefunktion ved baseline vurderet før behandling med Atripla initieres
That patients should have their baseline renal function assessed prior to initiating Atripla therapy
At patienterne bør have deres nyrefunktion ved baseline vurderet, før behandling med Viread initieres
That patients should have their baseline renal function assessed prior to initiating Viread therapy
at patienterne ikke må være i behandling med antitrombocytmidler eller andre antikoagulantia på injektionstidspunktet
that patients should not be taking anti-platelet or other anti-coagulation medicinal products at the time of injection
At patienterne skal bære kortet på sig og altid vise det til sundhedspersonale, som behandler for akutte anfald af hereditært angioødem.
That they should be asked to carry the card and always show it to any health care professional treating them for acute attacks of hereditary angioedema.
At patienterne skal rådes til at kontakte lægen vedrørende uønskede hændelser, og at lægerne/apoteket skal indrapportere formodede bivirkninger ved Eurartesim og især bivirkninger forbundet med QT-forlængelse.
That patients should be advised to contact their doctor about adverse events and that physicians/pharmacists should report suspected adverse reactions to Eurartesim, and in particular, those associated with a QT prolongation.
At patienterne skal være i stand til at efterkomme kravene om sikker anvendelse af thalidomid
That patients should be capable of complying with the requirements for the safe use of thalidomide
At patienterne, pga. risikoen for leverskader og anæmi, skal have taget regelmæssige blodprøver og skal fortælle lægen, hvis de får symptomer på leverskade.
That because of the potential for liver injury and anaemia, patients should have regular blood tests and also tell their doctor if experiencing any symptoms of liver injury.
At patienternes nyrefunktion bør vurderes og overvåges, og at initialdosis og dosistilpasning bør beregnes på baggrund af kreatininclearance.
That patients’ renal function should be assessed and monitored and initial dose and dosage adjustments should be calculated based on the creatinine clearance.
At PhotoBarr
That PhotoBarr
At pomalidomid er teratogent hos dyr og forventes at have teratogen virkning hos mennesker
That pomalidomide is teratogenic in animals and is expected to be teratogenic in humans
At pomalidomid kan forårsage neutropeni og trombocytopeni, og at regelmæssige blodprøver er nødvendige
That pomalidomide may cause neutropenia and thrombocytopenia and the need for regular blood tests
At produktet kun må anvendes én gang. oplysninger om overvågningsstudier efter markedsføringen, inklusive infomation om, hvordan patienter skal rekrutteres.
that the product should only be used once details of the post marketing surveillance studies including information on how to enroll patients
at reducere forhøjede calciumniveauer i blodet (hyperkalcæmi) hos patienter med biskjoldbruskkirte lkræft. at reducere forhøjede calciumniveauer i blodet (hyperkalcæmi) hos patienter med primær hyperparatyroidisme, hvor det ikke er muligt at fjerne biskjoldbruskkirtlen.
to reduce high levels of calcium in the blood (hypercalcaemia) in patients with parathyroid cancer. to reduce high levels of calcium in the blood (hypercalcaemia) in patients with primary hyperparathyroidism when removal of the gland is not possible.
at reducere forhøjede calciumniveauer i blodet (hyperkalcæmi) hos patienter med biskjoldbruskkirtelkræft. at reducere forhøjede calciumniveauer i blodet (hyperkalcæmi) hos patienter med primær hyperparatyroidisme, hos patienter, hvor det ikke er muligt at fjerne biskjoldbruskkirtlen.
to reduce high levels of calcium in the blood (hypercalcaemia) in patients with parathyroid cancer to reduce high levels of calcium in the blood (hypercalcaemia) in patients with primary hyperparathyroidism when removal of the parathyroid gland is not possible.